SG Growth Capital

SG Growth Capital is a Singapore-based government investment entity established in 2025 through the merger of EDBI and SEEDS Capital. Operating as the strategic investment arm of the Singapore Economic Development Board (EDB) and Enterprise Singapore, the firm focuses on fostering innovation and economic resilience by backing early-stage startups and growth-stage technology leaders. SG Growth Capital maintains a significant presence in the life sciences sector, investing in biotechnology, medtech, and healthcare companies to anchor high-potential ventures within Singapore. The organization provides portfolio companies with capital, strategic guidance, and access to extensive global networks to facilitate regional and international scaling. It plays a central role in the 'Singapore Biotech Bridge' program, collaborating with global partners like Novo Holdings and MPM BioImpact to support fast-growing Asian biotech companies.